分析师周五分享的 IQVIA 数据所显示， 诺和诺德 旗下减肥药Wegovy口服片剂在美国上市后的前四天内开出了3071张处方。投资者正密切关注，该公司能否在竞争激烈的减肥药物市场中，巩固其相对于竞争对手礼来的先发优势。
巴克莱分析师在报告中指出，这些数据仅反映零售渠道的口服Wegovy处方量，不包括通过诺和诺德自有的NovoCare Pharmacy在线渠道配发的处方，因此实际处方数量将更高。
分析师周五分享的 IQVIA 数据所显示， 诺和诺德 旗下减肥药Wegovy口服片剂在美国上市后的前四天内开出了3071张处方。投资者正密切关注，该公司能否在竞争激烈的减肥药物市场中，巩固其相对于竞争对手礼来的先发优势。
巴克莱分析师在报告中指出，这些数据仅反映零售渠道的口服Wegovy处方量，不包括通过诺和诺德自有的NovoCare Pharmacy在线渠道配发的处方，因此实际处方数量将更高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.